) Bausch + Lomb announces its strategic partnership with Munich Surgical Imaging GmbH (MSI) | Bausch + Lomb Surgical

Bausch + Lomb announces its strategic partnership with Munich Surgical Imaging GmbH (MSI)

MONTPELLIER, FRANCE, 30 August 2022 – As announced by Joe Papa earlier this year, Bausch + Lomb, a leading global eye health business, is thrilled to announce today its strategic partnership with Munich Surgical Imaging GmbH (MSI) – a wholly-owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state-of-the art digital visualization and image-guided surgical applications. The new MSI platform, developed specifically for the field of ophthalmology, is anticipated to receive regulatory approvals in late 2022 and it is expected to be showcased at key ophthalmic tradeshows during the second half of 2022.


We are proud to collaborate with MSI on bringing to market innovative surgical solutions,” said Luc Bonnefoy, Senior Vice President Surgical, Bausch + Lomb. “This partnership will combine MSI’s visualization and image guidance expertise, including an integrated high-speed SS-OCT powered by Heidelberg Engineering, with Bausch + Lomb’s surgical strengths in the cataract, refractive and vitreoretinal space to meet the increasing demand for digital microscopy.


The digitalization of surgical microscopy opens up a new world of possibilities for increasing surgical precision, improving outcomes, and empowering ophthalmologists in all sub-specialties to improve patient care,” said Kfir Azoulay, Head of Corporate Strategy at Heidelberg Engineering and co-Managing Director of MSI. “Our strategic collaboration with Bausch + Lomb in this area will allow surgeons to benefit from the combined strengths of both companies in the surgical field.”



About Bausch + Lomb
Bausch + Lomb, a leading global eye health business, is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices, and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.


About Munich Surgical Imaging (MSI)

Munich Surgical Imaging (MSI) is a technological pioneer in the field of digital microscopy and image-guided applications. Founded in 2011, the company’s first surgical platform in the field of ENT (Ear, Nose, and Throat) has received accolades from surgeons on key parameters, such as outstanding natural 3D image quality and blending of 3D image with preoperative data. The company’s brand-new ophthalmology platform is expected to be introduced in late 2022.

MSI’s state-of-the-art OCT technology is powered by its parent company, Heidelberg Engineering, a global leader in the field of diagnostic imaging and healthcare IT solutions for ophthalmology.




Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.